Quarterly ResultAug 12, 2026, 04:16 PM
Decoy Therapeutics Reports Increased Net Loss, Going Concern Doubt
AI Summary
Decoy Therapeutics Inc. reported a significant increase in net loss for the three and six months ended June 30, 2026, reaching $(2.37) million and $(4.60) million, respectively. The company also disclosed substantial doubt about its ability to continue as a going concern, citing insufficient cash to fund operations for the next year without additional capital. Despite a recent private placement raising $3.5 million in June 2026, the company's cash and stockholders' equity decreased from year-end 2025.
Key Highlights
- Net loss for Q2 2026 increased to $(2.37) million from $(0.96) million in Q2 2025.
- Net loss for H1 2026 increased to $(4.60) million from $(2.67) million in H1 2025.
- Cash, cash equivalents, and restricted cash decreased to $8.29 million at June 30, 2026, from $10.71 million at Dec 31, 2025.
- Total stockholders' equity decreased to $4.32 million at June 30, 2026, from $5.89 million at Dec 31, 2025.
- Company raised approximately $3.5 million gross proceeds from a private placement in June 2026.
- Research and development expenses for H1 2026 surged to $2.05 million from $0.19 million in H1 2025.
- Company expressed substantial doubt about its ability to continue as a going concern.
Price Impact
More from DCOY